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Paediatric hepatoblastoma and
hepatocellular carcinoma: retrospective
study
Objectives. To compare and contrast clinical characteristics and outcomes of
hepatoblastoma or hepatocellular carcinoma in paediatric patients.
Design. Retrospective study.
Setting. University teaching hospital, Hong Kong.
Patients and methods. Medical records of 22 paediatric patients with
hepatoblastoma (n=11) or hepatocellular carcinoma (n=11) admitted to Queen
Mary Hospital between 1989 and 2000 were reviewed. Data gathered included
demographic data, results of liver function tests, hepatitis A, B, and C titres, and
α-foetoprotein levels, and imaging studies including chest X-ray, ultrasound study,
computed tomography scan, and magnetic resonance imaging / hepatic angiogram
for tumour staging and resectability.
Results. The mean age of patients with hepatoblastoma was 18 months (range,
5 months to 3 years), while that of patients with hepatocellular carcinoma was
10.2 years (range, 2 to 16 years). Females predominated in the hepatoblastoma
group (female:male, 8:3) and males in the hepatocellular carcinoma group (male:
female, 10:1). None of the patients with hepatoblastoma were hepatitis B surface
antigen positive, in contrast to 64% of the hepatocellular carcinoma group. Only
45% of the hepatocellular carcinomas were resectable at presentation and this
figure remained unchanged following chemotherapy. A total of 91% of
hepatoblastomas were resectable, four at presentation, and a further six after
chemotherapy. Tumour rupture was more common in patients with
hepatoblastoma than in those with hepatocellular carcinoma (36% versus 9% of
cases, respectively). Mortality rates were considerably higher among the
hepatocellular carcinoma group than the hepatoblastoma group in this series.
Conclusion. Childhood hepatoblastoma and hepatocellular carcinoma differ with
respect to age and tumour stage at presentation, hepatatis B surface antigen status,
tendency to rupture, chemosensitivity, and prognosis.
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Introduction
Primary neoplasms of the liver constitute 0.5% to 2.0% of
paediatric tumours in large series, and malignant epithelial
neoplasms constitute two thirds of the primary hepatic
tumours in infancy and childhood.1 Exelby et al2 found that
hepatoblastoma (HB) and hepatocellular carcinoma (HCC)
were the most common primary epithelial liver tumours in
children following a large questionnaire survey conducted
in the US. A previous study at the Queen Mary Hospital
suggested that HB and HCC may be equally common in the
Hong Kong paediatric population.3
After studying 47 cases of HB and HCC, Ishak and
Glunz4 concluded in 1967 that patients with HCC had a poor
prognosis regardless of the treatment offered but that surgical
excision for HB did influence survival. Since this early study,
there have been significant improvements in the results from
hepatic resection5 and with preoperative chemotherapy for
initially unresectable HB.6 Paediatric patients treated at
Queen Mary Hospital for HB or HCC were reviewed in order
to compare these tumours with respect to patient age and
stage of tumour at presentation, associated factors, resect-
ability, response to chemotherapy, and overall prognosis
given recent advances in treatment.
Methods
The medical records of all paediatric patients with HB or
HCC admitted to Queen Mary Hospital between 1989 and
2000 were reviewed. The diagnosis of HB or HCC was
confirmed histologically. Laboratory investigations
completed included liver function tests, hepatitis A, B,
and C titres, and serum α-foetoprotein levels. Imaging
studies included chest X-ray, ultrasonography, computed
tomography (CT) scan, and hepatic angiography with or
without magnetic resonance imaging for tumour staging and
resectability. The International Society of Paediatric
Oncology (SIOP) method of staging was used: Stage I, one
liver segment involved; Stage II, two segments involved;
Stage III, three segments involved or two isolated, separate
segments involved; Stage IV, all four segments involved.7,8
The segments were delineated using Couinaud’s liver
segments.9 Substaging was indicated by subscripts to the
above stages, such as ‘m’ for metastasis, or ‘p’ for portal
vein involvement.
For unresectable tumours, biopsies were taken and
systemic chemotherapy commenced to reduce tumour size,
following the Paediatric Oncology Group regimens.6,10
The induction drug used was carboplatin (500 mg/m2),
followed by a triple drug regimen of carboplatin (500 mg/m2),
vincristine (1.5 mg/m2), and 5-fluorouracil (600 mg/m2).
Blood was taken from the patients after 3 weeks to assess
recovery of leukocyte and platelet counts. The cycle of chemo-
therapy was repeated if leukocyte and platelet counts were
normal. Transarterial oily chemoembolisation (TOCE)
treatment with cisplatin was given to patients with inoperable,
locally extensive HCC. Imaging studies were repeated
regularly to assess tumour response and resectability.
Patients with ruptured tumours confirmed on CT scan
underwent immediate cardiovascular resuscitation.
Depending on the stage of the tumour as seen on the CT
scan and the condition of the patient, stoppage of bleeding
was accomplished by transcutaneous hepatic artery
embolisation, selective hepatic artery ligation, or hepatic
resection. Only clinically stable, small tumours were resected
as an emergency procedure.
Results
Between 1989 and 2000, 22 patients were treated for HB
(n=11) and HCC (n=11) in Queen Mary Hospital (Table 1).
The mean age of patients with HB was 18 months (range,
5 months-3 years), while that of patients with HCC was
10.2 years (range, 2-16 years). Females predominated among
the patients with HB (male:female, 3:8), and males among
those with HCC (male:female, 10:1). While 64% (7/11) of
the HCC patients were hepatitis B surface antigen (HBsAg)
positive, none of the patients with HB were HBsAg positive.
Younger patients with HCC (2, 5, and 8 years) also were
negative for HBsAg. The mean serum α-foetoprotein level
was higher for patients with HB (28 183 µg/L; normal level,
<10 µg/L) than the HCC patients (4216 µg/L).
The tumour rupture rate was higher in the HB group
(4/11, 36%) than in the HCC group (1/11, 9%). One patient
in the HB group died within 1 day of admission before a
diagnosis of ruptured tumour could be made, but all other
patients with HB and ruptured tumour (n=4) had their
bleeding stopped by embolisation (n=2), right hepatic artery
ligation (n=1), or emergency lobectomy (n=1). These four
patients were without evidence of disease after tumour
resection and chemotherapy at the time of writing (mean
survival, 3 years; range, 2-4 years). The only patient with a
ruptured HCC underwent right lobectomy after stoppage of
bleeding and died 5 months later due to tumour recurrence.
Table 1. Characteristics of patients with hepatoblastoma or hepatocellular carcinoma at presentation
Mean age Sex Hepatitis B Mean serum Resectable tumour Tumour
(range) (male: female) surface antigen alpha-foeto- at presentation or rupture
 status positive protein level following chemotherapy No. (%)
No. (%) (µg/L) No. (%)
Hepatoblastoma 18 months 3:8 0 (0) 28 183 10 (91) 4 (36)
(n=11) (5 months-3 years)
Hepatocellular 10.2 years
carcinoma (n=11) (2-16 years) 10:1 7 (64) 4216 5 (45) 1 (9)
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The HCC tumours demonstrated a tendency to enlarge
and infiltrate early in the clinical course (Table 2), with
seven (64%) patients found to have Stage IV tumours at
presentation. A Stage I HCC was identified in a patient with
neonatal hepatitis, with follow-up ultrasound scanning
locating a 2-cm nodule at the left lateral hepatic segment.
This patient has since been tumour-free for 3 years following
left lateral segmentectomy.
A total of 15 hepatic resections were performed: five
for HCC (45%) and 10 for HB (91%). Six patients had HB
tumours deemed suitable for resection following chemo-
therapy treatment, while such a response to chemotherapy
was not seen in any patients with unresectable HCC. Oper-
ations included right lobectomy (n=6), right trisegmentec-
tomy (n=2), right lateral segmentectomy (n=1), left
trisegmentectomy (n=3), left lobectomy (n=1), left lateral
segmentectomy (n=1), and left lateral segmentectomy with
partial gastrectomy and transverse colectomy (n=1). The
right lateral segmentectomy involved resection of segments
six and seven only in order to preserve as much liver tissue
as possible. Blood loss during surgery ranged from 250 cc
to 1750 cc (mean, 525 cc). There was no operative mortality.
One patient experienced subphrenic haematoma formation
and required a second operation for blood evacuation. All
other patients had an uneventful recovery postsurgery.
Survival rates were higher overall for patients with HB
than for those with HCC (Fig): median survival of 3 years
versus 5 months, respectively (P=0.0001, log rank test). One
patient with HB and tumour rupture (undiagnosed) died
shortly after admission. Another patient with HB and raised
α-foetoprotein levels 9 months after hepatic resection, was
found to have three secondary tumours (one in the left lobe
and two in the right lobe) on CT of the thorax. Left thoraco-
tomy and partial pulmonary resection for the removal of the
left nodule confirmed the secondary tumours histologically.
The patient is awaiting further surgery to remove the right
nodules. All other HB patients are well without evidence of
disease. Of the patients with HCC, only three are still alive.
One is without evidence of disease while two have persistent
HCC and are undergoing TOCE treatment for tumour
control.
Discussion
Surgical techniques designed to reduce intraoperative blood
loss, blood transfusion, and ischaemic injury to the liver
remnant following hepatectomy, together with postoperative
care, have been improving and are reducing hospital
mortality associated with hepatectomy towards zero.5,11,12
Paediatric patients have a small blood volume, and have
been found to have better results than older patients.13,14 In
the 15 hepatectomies reported here, there was no surgical
mortality and the only morbidity was a single instance of
subphrenic haematoma requiring a second operation for
blood evacuation. With careful surgical techniques and good
postoperative care, hepatectomy has been shown to be a safe
procedure for paediatric patients in this series, with a mean
blood loss of 525 cc.
Late presentation posed a major management problem
for the patients in this study. In this series, only 45% (Table
1) of patients with HCC and 36% of patients with HB had
resectable tumours at presentation. Fortunately, the HB
tumours were chemosensitive, with six patients able to
undergo resection after chemotherapy. All patients with
HB therefore underwent hepatectomy, except the patient
who died prior to diagnosis. One patient had secondary
pulmonary tumours and was treated with thoracotomy and
lung resection. A similar patient has been reported in
the literature to have long-term survival.15 Because of the
chemosensitivity of HB, more aggressive treatment for more
extensive tumours has been attempted, including transarterial
chemotherapy and liver transplantation.15-17 The results for
HCC treatment, in contrast, have been poor. No patient in
this series was able to undergo surgical resection of the tumour
following chemotherapy. Transarterial oily chemoemboli-
sation has been reported for the prolongation of life, though
the mean survival achieved was only 5 months.18 Hepatitis
B surface antigen–positive patients with HCC have a higher
Table 2. Tumour stage at presentation according to the
International Society of Paediatric Oncology staging method
Hepatoblastoma Hepatocellular carcinoma
No. (%) No. (%)
Stage I 1 (9) Stage I 1 (9)
Stage II 3 (27) Stage II extension 1 (9)
Stage III 7 (64) Stage III portal vein 1 (9)
Stage III metastasis 1 (9)
Stage IV 6 (55)
Stage IV metastasis 1 (9)
Fig. Survival curve for patients with hepatoblastoma and
hepatocellular carcinoma
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mortality rate, suggesting that they make poor candidates
for liver transplantation.19 In this study, the only patient who
survived for 3 years was one identified on a screening ultra-
sound study for postneonatal hepatitis. Screening for early
disease may enhance the survival rate of patients with HCC.20
The SIOP staging system for paediatric hepatic tumours
has been confirmed as useful for comparing results of
different treatment options.7,8 It is a preoperative clinical
staging system, with the emphasis on local extension and
vascular invasion. The system differs from the International
Union Against Cancer (UICC) TNM staging system com-
monly used in adults. Modification of the adult UICC TNM
staging system, placing greater emphasis on vascular
invasion has been suggested by Izumi et al21 and Staudacher
et al22 following their studies investigating treatment results
of patients with HCC. The SIOP staging system addresses
the infiltrative status of tumours and this may explain its
prognostic accuracy with respect to paediatric hepatic
tumours, especially paediatric HCC which is very infiltrative
and aggressive (Table 2).
Rupture has not been included as a variable in the SIOP
staging system. In selected patients and with appropriate
treatment, survival is possible.23 The mechanism of
spontaneous rupture of liver tumour is unknown. It may be
related to venous congestion, haemorrhage, central necrosis,
or trauma.24 Embolisation, emergency hepatectomy, and
selective hepatic artery ligation are reported treatments25-28
and were successfully applied in this study to arrest
postrupture bleeding. The preferred treatment depends on
the general condition of the patient, tumour size, and the
experience of the surgeon. Selective hepatic artery ligation
did not appear to affect postligation chemotherapy for
the patients in this study. There were apparently sufficient
collateral vessels remaining to allow postoperative chemo-
therapy to control the tumour. Rupture in HB did not appear
to negatively influence patient survival, except in the patient
in whom the diagnosis of ruptured HB was not made.
The prognosis for paediatric patients with HCC appears
poor (Fig).29 The resection rate in this study was 45%, and
the median survival time in this series only 5 months.
Hepatitis B surface antigen tests were positive in 64% of
the patients overall. Those who tested positive were the older
patients in the group. In younger patients, the development
of HCC has been attributed to a variety of conditions,
including tyrosinaemia, biliary atresia, idiopathic neonatal
hepatitis, and neonatal iron storage disease.30 Idiopathic
neonatal hepatitis was found in one of the current patients.
Universal hepatitis B vaccination is known to decrease the
incidence of HCC.31 Since hepatitis vaccination has
commenced in Hong Kong, the local incidence of HCC is
expected to decrease.
The aetiology of HB is currently unknown. All of the
patients with HB in the current series were HBsAg negative.
Prematurity has been shown to be associated with HB,32,33
but the exact mechanism is unclear. The alteration of genes
involved with cell cycle control and cell growth, as well as
chromatin modification, have been noted in patients with
HB.34 Similar genetic aberrations, such as p53 mutations,
have also been found in patients with HCC.35,36 The use of
molecular techniques to investigate these tumours and the
differences between them still remains to be addressed in
research studies.
Conclusion
Paediatric HB and HCC demonstrate marked differences in
their clinical course. These differences should be kept in
mind when planning management for paediatric patients
with HB or HCC, and counselling patients and their families.
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